Liquidia (NASDAQ:LQDA) Insider Rajeev Saggar Sells 9,218 Shares of Company Stock

Posted by Geri Gentry on Oct 14th, 2026

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) insider Rajeev Saggar sold 9,218 shares of the company’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $262,528.64. Following the transaction, the insider directly owned 126,368 shares in the company, valued at $3,598,960.64. This represents a 6.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Rajeev Saggar also recently made the following trade(s):

On Monday, August 17th, Rajeev Saggar sold 29,534 shares of Liquidia stock. The stock was sold at an average price of $76.84, for a total value of $2,269,392.56.
On Wednesday, August 19th, Rajeev Saggar sold 50,000 shares of Liquidia stock. The stock was sold at an average price of $74.06, for a total value of $3,703,000.00.

Liquidia Trading Down 3.1%

Shares of LQDA opened at $26.81 on Wednesday. The business has a 50-day moving average of $63.40 and a 200 day moving average of $61.76. Liquidia Corporation has a fifty-two week low of $21.94 and a fifty-two week high of $93.61. The firm has a market cap of $2.40 billion, a P/E ratio of 19.57 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31.

Liquidia (NASDAQ:LQDA – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The firm had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The company’s revenue was up 1842.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.49) earnings per share. As a group, research analysts forecast that Liquidia Corporation will post 2.05 EPS for the current year.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Institutional Trading of Liquidia

A number of hedge funds and other institutional investors have recently bought and sold shares of LQDA. WINTON GROUP Ltd bought a new position in Liquidia in the 2nd quarter valued at $335,000. Arizona State Retirement System grew its position in shares of Liquidia by 5.4% during the 2nd quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock valued at $1,405,000 after purchasing an additional 900 shares in the last quarter. Nykredit A S bought a new position in shares of Liquidia in the second quarter worth $177,000. Corient Private Wealth LP bought a new position in shares of Liquidia in the second quarter worth $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Liquidia in the second quarter worth $1,236,000. Institutional investors own 64.54% of the company’s stock.

Analyst Upgrades and Downgrades

LQDA has been the topic of several research reports. Piper Sandler set a $129.00 price target on shares of Liquidia in a research report on Friday, July 24th. Stephens set a $130.00 price objective on shares of Liquidia in a report on Friday, July 24th. Royal Bank Of Canada set a $130.00 price objective on shares of Liquidia in a report on Friday, July 24th. Wall Street Zen lowered shares of Liquidia from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Finally, Wells Fargo & Company reissued an “equal weight” rating and set a $30.00 target price (down from $108.00) on shares of Liquidia in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Liquidia presently has a consensus rating of “Hold” and an average price target of $83.69.

Read Our Latest Research Report on Liquidia

Liquidia Company Profile

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).